Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Dow
Colorcon
AstraZeneca
Express Scripts
Johnson and Johnson

Last Updated: November 16, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,318,706

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,318,706 protect, and when does it expire?

Patent 8,318,706 protects SEYSARA and is included in one NDA.

This patent has thirty patent family members in fourteen countries.

Summary for Patent: 8,318,706
Title:Substituted tetracycline compounds
Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms.
Inventor(s): Kim; Oak (Cambridge, MA), Assefa; Haregewein (Braintree, MA), Honeyman; Laura (Roslindale, MA)
Assignee: Paratek Pharmaceuticals, Inc. (Boston, MA)
Application Number:11/963,540
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Drugs Protected by US Patent 8,318,706

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Almirall SEYSARA sarecycline hydrochloride TABLET;ORAL 209521-001 Oct 1, 2018 RX Yes No   Start Trial   Start Trial Y Y A METHOD FOR TREATING A BACTERIAL INFECTION IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE   Start Trial
Almirall SEYSARA sarecycline hydrochloride TABLET;ORAL 209521-002 Oct 1, 2018 RX Yes No   Start Trial   Start Trial Y Y A METHOD FOR TREATING A BACTERIAL INFECTION IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE   Start Trial
Almirall SEYSARA sarecycline hydrochloride TABLET;ORAL 209521-003 Oct 1, 2018 RX Yes Yes   Start Trial   Start Trial Y Y A METHOD FOR TREATING A BACTERIAL INFECTION IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
McKesson
Express Scripts
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.